Literature DB >> 26939563

Comment on: 896.

D Călugăru1, M Călugăru1.   

Abstract

Year:  2016        PMID： 26939563      PMCID： PMC4906446          DOI： 10.1038/eye.2016.31

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.

Authors:  L C Olmos; M S Sayed; A L Moraczewski; S J Gedde; P J Rosenfeld; W Shi; W J Feuer; R K Lee
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

2.  Prevention of neovascular glaucoma.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Ophthalmology       Date:  2013-07       Impact factor: 12.079

3.  [Results of a survey on the occurrence of neovascular glaucoma after central retinal vein occlusion].

Authors:  M Càlugàru
Journal:  J Fr Ophtalmol       Date:  1987       Impact factor: 0.818

4.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

5.  [Consensus on neovascular glaucoma].

Authors:  P Hamard; C Baudouin
Journal:  J Fr Ophtalmol       Date:  2000-03       Impact factor: 0.818
  5 in total
  3 in total

Review 1.  Intraocular pressure modifications in patients with acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

Review 2.  Etiology, pathogenesis, and diagnosis of neovascular glaucoma.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2022-06-18       Impact factor: 1.645

Review 3.  Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru; Ștefan Țălu
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.